OPKO Health agrees to sell lab testing assets to LabCorp for up to $872 million

On October 14, 2026, OPKO Health, Inc., its wholly owned subsidiary BioReference Health, LLC, and Laboratory Corporation of America Holdings entered into an Asset Purchase Agreement.¹ Under the deal, BioReference agreed to sell and assign certain assets of its clinical and anatomic pathology laboratory testing business to LabCorp, including assets focused on clinical and women's health testing services, urology, corrections, and the 4Kscore prostate cancer test, along with certain related liabilities.¹

The transaction terms call for LabCorp to pay $722,000,000 in cash at closing, subject to upward or downward adjustments based on business revenues at closing, plus up to $150,000,000 in cash over as long as ten years tied to revenue from sales of the 4Kscore test.¹

Closing is conditioned on standard requirements. These include accuracy of the parties' representations and warranties, performance of covenants, and expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.¹ The deal is not subject to a financing condition.¹

The agreement includes an outside date. Either party may terminate if the transaction has not closed by April 14, 2027, unless the parties agree to extend, or if a government order blocks or prohibits the deal.¹ If the deal is terminated because HSR clearance or other required approvals are not obtained, LabCorp would owe OPKO a termination fee of $28,880,000.¹

The agreement also restricts BioReference and OPKO from pursuing alternatives. Seller agreed not to solicit or engage in discussions with third parties about alternative transactions involving the business while the deal is pending.¹

The filing noted that the summary is qualified by the full Purchase Agreement, filed as Exhibit 2.1 to the Form 8-K.¹ The report was signed by Adam Logal, OPKO's Senior Vice President and Chief Financial Officer, dated October 15, 2026.